GUJINJEC.BO · BSE

GUJARAT INJECT (KERALA) LTD.

₹9.17

-1.08% (-₹0.1)

Prev. close

₹9.27

Volume

1

As of

BSE · may be slightly delayed · 12:56 IST

Price history

₹9.27-₹110.93 (-92.29%) · 3M
22 Jun 202623 Sept 2026
₹132.7₹9.0822 Jun15 Jul07 Aug31 Aug23 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on GUJARAT INJECT (KERALA) LTD. in the last 90 days.

Fundamentals

About GUJARAT INJECT (KERALA) LTD.

Gujarat Inject (Kerala) Limited engages in the business of trading of goods. The company was incorporated in 1991 and is based in Vadodara, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Murli Shivshankaran Nair

Headquarters

Vadodara

Employees

4

Key stats

Market cap

₹135.80 Cr

P/E ratio (TTM)

44.1

EPS (TTM)

₹0.21

Beta (1Y · daily vs NIFTY 50)

-0.01

Beta (5Y · monthly vs NIFTY 50)

-1.19

Shares float

35.19 L

EPS · quarter ended Jun 2026

₹0.09

Financial Performance

01 · Financials

0 Cr10 Cr20 Cr30 Cr40 Cr0%1000%2000%3000%4000%FY22FY23FY24FY25FY26
RevenueNet incomeRevenue growth YoY

Revenue for Mar 2022–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2021 revenue as filed with BSE; the two sources' revenue definitions differ by 0.1% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.

02 · Earnings Per Share (EPS)

0000FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-2000%0%2000%4000%FY22FY23FY24FY25FY26
SalesTrade receivables

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr10 Cr20 Cr30 Cr40 Cr0.5×1.5×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr10 Cr20 Cr30 Cr40 CrFY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-10 Cr-5 Cr0 Cr5 CrFY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1.20 L₹2.30 L₹17.38 L₹5.79 Cr₹19.05 Cr₹36.32 Cr
EBITDA₹5.55 L₹10.57 L₹1.26 Cr₹2.50 Cr
₹-10.50 L₹20,000₹4.10 L₹8.28 L₹1.02 Cr₹1.81 Cr
Diluted EPS₹0.01₹0.01₹0.07₹0.12

Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹30.32 L₹8.69 Cr₹11.95 Cr₹36.67 Cr
₹60.77 L₹0₹0₹0
Stockholders' equity₹-83.74 L₹8.55 Cr₹10.01 Cr₹11.83 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31, 2024-03-31, 2025-03-31, 2026-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2023-03-31, 2024-03-31, 2025-03-31, 2026-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹5.26 L₹-6.03 Cr₹-3.52 Cr₹21.22 Cr
Investing cash flow₹15,630₹2,803₹17.92 L₹-20.57 Cr
₹0₹8.88 Cr₹45.00 L₹0
Capital expenditure₹-20.76 Cr
End cash position₹6.17 L₹2.92 Cr₹2.63 L₹67.82 L

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,846.437.15.3713.7%0.06+11.9%+12.3%
Divi's Laboratories Limited₹2.48 L Cr₹9,62484.914.8115.3%0.00+12.3%+59.0%
Torrent Pharmaceuticals Limited₹1.88 L Cr₹4,98578.822.3825.8%1.79+21.5%+36.5%
Apollo Hospitals Enterprise Limited₹1.28 L Cr₹8,835.561.513.5220.5%0.90+15.7%+14.2%
Lenskart Solutions Limited₹1.20 L Cr₹686.7181.013.705.6%0.35+35.4%
Zydus Lifesciences Limited₹1.16 L Cr₹1,170.125.94.2818.6%0.46+18.4%+12.0%
Cipla Limited₹1.12 L Cr₹1,384.133.23.2511.3%0.02+2.1%-10.3%
Laurus Labs Limited₹1.09 L Cr₹2,03499.720.5216.8%0.48+22.0%+123.5%
Max Healthcare Institute Limited₹1.02 L Cr₹1,066.670.49.5013.4%0.32+19.0%-8.0%
Dr. Reddy's Laboratories Limited₹1.01 L Cr₹1,211.230.52.6811.4%0.21+3.2%-7.4%
Manipal Health Enterprises Limited₹99,126.82 Cr₹760.95150.711.767.8%1.53+18.0%
GUJARAT INJECT (KERALA) LTD.₹140.63 Cr₹9.648.011.8915.3%0.00+90.7%-52.0%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

GUJINJEC.BO

Gujarat Inject Kerala pivots to renewable energy, reports fivefold Q1 revenue growth

Gujarat Inject Kerala is transitioning its business to renewable energy and plans to rebrand as Regenova Renewtech Ltd. The company reported a fivefold increase in Q1 FY27 revenue and secured solar panel orders worth approximately INR 15.56 crore. This shift aligns with India's growing renewable energy sector.

GUJINJEC.BO

Gujarat Inject Kerala Enters TESS Pact; Shares Rise Nearly 5%

HDFC Sky · 1 month ago